CN

CN
News
News
News
Always Share with You
Every Bit of Our Progress
Home > News > Details
MicroPort® CardioFlow Receives Approval for VitaFlow Liberty® in Argentina,Marking the Next Step in Its International Expansion
2022-01-06
Back

Shanghai, China - MicroPort® CardioFlow Medtech Corporation (hereinafter referred to as MicroPort® CardioFlow", stock code: 02160.HK) announced that its self-developed VitaFlow Liberty® Transcatheter Aortic Valve and Retrievable Delivery System (hereinafter referred to as "VitaFlow Liberty®"), a new generation product for Transcatheter Aortic Valve Implantation (TAVI), has been approved by the Argentine National Administration of Drugs, Foods, and Medical Devices (ANMAT).

 

Since VitaFlow® Transcatheter Aortic Valve System (hereinafter referred to as " VitaFlow® "), the first-generation TAVI product of MicroPort® CardioFlow, was implanted commercially overseas for the first time in Dr. Julio Mendez Hospital of Argentina in August 2021, MicroPort® CardioFlow has successfully carried out TAVI operations in several hospitals in Argentina.

 

In October, 2021, the largest cardiovascular academic conference in Latin America-"SOLACI-CACI 21 "and MicroPort® CardioFlow jointly held an online seminar called" Challenges in TAVI-Severe CAD and Coronal Occlusion ". Dr. Diego Grinfeld and Dr. Jose Alvarez, presidents of Argentine Society of Interventional Cardiology, co-chaired the seminar, and experts from Argentina and China shared their experiences in TAVI treatment. This online meeting not only laid a good academic foundation for the sustainable development of MicroPort® CardioFlow in Latin America, but also set a new academic benchmark in the field of structural heart disease in China and Latin America.

 

VitaFlow Liberty® is the world’s only electric retrievable transcatheter aortic valve system, offering outstanding stability during procedure and hemodynamics post-procedure that will improve the quality of life for patients with aortic valve disease. It inherits the advantages of the VitaFlow® in terms of valve design, featuring a hybrid density self-expanding stent, bovine pericardial leaflets, and a high double-layer PET skirt design. This design offers robust radial force, improved coaxiality during deployment, and effectively reduces the incidence of perivalvular leakage post-procedure. Moreover, its breakthrough upgraded delivery system incorporates a unique and innovative double-reinforced spiral structure that ensures rapid, stable, and precise release and retrieval. This system also provides flexibility, allowing for 360-degree bending of the valve segment.

 

The endorsement of VitaFlow Liberty® will help MicroPort® CardioFlow to enter more overseas potential markets more quickly. In the future, MicroPort® CardioFlow will continue to adhere to the mission of "providing trustworthy and universal access to state-of-the-art total solutions to treat structural heart diseases", further give play to the advantages of the platform, accelerate the launch of innovative products with international competitiveness, and promote the "China-created" total medical solution for structural heart disease in the international mainstream product competition.

Privacy settings

This website may store cookies on your browser. Cookies are mostly used to make the website work asyou expect it to. No cookie will directly identify you, but it can give you a more personalized browsingexperience.


CardioFlow Medtech respects your privacy rights, so you can block some types of cookies. Technically non-essentialcookies and tracking mechanisms, that enable us to provide you with customized offers (marketingcookies), are only used if you have given prior consent to such use.

By clicking "Save", only the cookies you selected will be used. You can withdraw the consent that you granted here at any time by going to Cookies Settings. For more information, please see our Cookie Policy.

×
TOP

©Copyright 1998-2023, MicroPort CardioFlow Medtech Corporation. All rights reserved. | 网站备案/许可证号:沪ICP备2023023560号 沪公网安备 31011502014876号

互联网药品信息服务资格证书编号:(沪)-非经营性 - 2024 - 0135

“MicroPort CardioFlow”及“ are registered trademarks of MicroPort CardioFlow Medtech Corporation.